Market Overview

Actavis to Acquire Forest Labs for ~$25B in Equity, Cash; Both Stocks Surge Higher


Tuesday morning Actavis (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) announced an agreement under which Actavis will acquire Forest for a combination of cash and equity valued at $25 billion, or $89.48 per Forest share.

The terms of the deal are 26.04 in cash and 0.3306 Actavis shares for each share of FRX common stock. This represents a premium of 25 percent over Forest's share price.

Rumors of the deal were first reported by The Wall Street Journal late Monday night.

The acquisition is expected to yield double-digit accretion to non-GAAP earnings in 2015 and 2016, with significant annual free cash flow generation of greater than $4 billion in 2015, allowing Actavis to rapidly de-lever.

Paul Bisaro, CEO of Actavis, will lead the combined company. Three members of the Forest Board of Directors will be named to the Actavis Board.

Shares of Forest have since continued their accent and are currently trading north of $95, up 36 percent. Shares of Actavis are up 14 percent and trading above $220.

Posted-In: M&A News Hot


Related Articles (FRX + ACT)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar(R)) in Hepatocellular Cancer

UPDATE: Medtronic Posts In-Line Q3 Earnings